{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:18:12Z","timestamp":1788247092771,"version":"build-2803163510"},"reference-count":66,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":133,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP121010"],"award-info":[{"award-number":["RP121010"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["1S10OD024977-01"],"award-info":[{"award-number":["1S10OD024977-01"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["1 R50 CA243707-01A1"],"award-info":[{"award-number":["1 R50 CA243707-01A1"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Immune checkpoint blockers (ICB) improve outcomes in metastatic melanoma (MM), but resistance limits benefit. This phase I\/II (NCT02706353) study evaluated intratumoral sotigalimab (anti-CD40 agonist) with pembrolizumab in 32 patients with ICB-na\u00efve MM. Primary endpoints were safety and objective response rate (ORR). Sotigalimab was well tolerated. At the recommended phase II dose, the ORR was 50%, and the disease control rate was 92%, with ORRs of 67% in injected and 50% in non-injected tumors. Multiomic analyses of tumor and blood showed that sotigalimab effectively engaged the CD40 pathway, boosting infiltration and activation of myeloid cells, including CD11c+DC-LAMP+ dendritic cells and macrophages. The combination therapy activated innate and adaptive immunity in injected tumors and cytotoxic responses in non-injected tumors. T-cell receptor sequencing showed increased T-cell clonality with expanded new clones shared across tumors. Clinical responses correlated with these immunologic changes but not with baseline features associated with response to anti\u2013PD-1 monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>In this study, we provide compelling data that intratumoral sotigalimab combined with pembrolizumab is safe, activates antigen-presenting cells, and elicits broad innate and adaptive immune responses in both injected and non-injected tumors, supporting further randomized phase II trials to evaluate sotigalimab\u2019s potential to enhance anti\u2013PD-1 therapy through \u201cin situ\u201d immunization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-25-1551","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T19:02:22Z","timestamp":1776798142000},"page":"1780-1800","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I\/II Study"],"prefix":"10.1158","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9824-107X","authenticated-orcid":false,"given":"Salah-Eddine","family":"Bentebibel","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Melanoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6669-6069","authenticated-orcid":false,"given":"Daniel J.","family":"McGrail","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 2 Department of Systems Biology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2614-3790","authenticated-orcid":false,"given":"Veena","family":"Kochat","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 3 Department of Genomic Medicine, , Houston, Texas."},{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 4 MDACC Epigenomics Therapy Initiative (METI), , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7224-917X","authenticated-orcid":false,"given":"Emre","family":"Arslan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 3 Department of Genomic Medicine, , Houston, Texas."},{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 4 MDACC Epigenomics Therapy Initiative (METI), , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5432-5068","authenticated-orcid":false,"given":"Reham","family":"Abdel-Wahab","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Melanoma Medical Oncology, , Houston, Texas."},{"name":"5Department of Clinical Oncology, Assiut Faculty of Medicine, Assiut University, Assiut, Egypt."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5255-8327","authenticated-orcid":false,"given":"Barbara","family":"Pazdrak","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Melanoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1395-3890","authenticated-orcid":false,"given":"Ravi","family":"Murthy","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 6 Department of Interventional Radiology and Investigational Cancer Therapeutics, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5863-0219","authenticated-orcid":false,"given":"Nourel Hoda M.","family":"Tahon","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 7 Department of Abdominal Imaging, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5758-8285","authenticated-orcid":false,"given":"Sung-Nam","family":"Cho","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Melanoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6763-9736","authenticated-orcid":false,"given":"Dzifa Y.","family":"Duose","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 8 Department of Translational Molecular Pathology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2383-3908","authenticated-orcid":false,"given":"Khalida M.","family":"Wani","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 8 Department of Translational Molecular Pathology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3197-2463","authenticated-orcid":false,"given":"Jingjing","family":"Liu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 3 Department of Genomic Medicine, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1317-9287","authenticated-orcid":false,"given":"Cara","family":"Haymaker","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 8 Department of Translational Molecular Pathology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6579-744X","authenticated-orcid":false,"given":"Javier A.","family":"Gomez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 9 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5376-7203","authenticated-orcid":false,"given":"Heather","family":"Sonnemann","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Melanoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-3056","authenticated-orcid":false,"given":"Arjun S.","family":"Katailiha","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Melanoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-2456","authenticated-orcid":false,"given":"Barbara","family":"Nassif-Rausseo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Melanoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6756-5802","authenticated-orcid":false,"given":"Maha","family":"Rahim","sequence":"additional","affiliation":[{"name":"10Enable Medicine, Menlo Park, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-9010","authenticated-orcid":false,"given":"Irene","family":"Li","sequence":"additional","affiliation":[{"name":"10Enable Medicine, Menlo Park, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6429-0420","authenticated-orcid":false,"given":"Aaron T.","family":"Mayer","sequence":"additional","affiliation":[{"name":"10Enable Medicine, Menlo Park, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6327-0604","authenticated-orcid":false,"given":"Xiaodong","family":"Yang","sequence":"additional","affiliation":[{"name":"11Pyxis Oncology, Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4156-2995","authenticated-orcid":false,"given":"Frank J.","family":"Hsu","sequence":"additional","affiliation":[{"name":"11Pyxis Oncology, Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1138-9919","authenticated-orcid":false,"given":"Jianhua","family":"Zhang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 3 Department of Genomic Medicine, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4778-686X","authenticated-orcid":false,"given":"Daniel H.","family":"Johnson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Melanoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6876-278X","authenticated-orcid":false,"given":"Rodabe N.","family":"Amaria","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Melanoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4530-7765","authenticated-orcid":false,"given":"Isabella C.","family":"Glitza Oliva","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Melanoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-1517","authenticated-orcid":false,"given":"Sapna P.","family":"Patel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Melanoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8293-1313","authenticated-orcid":false,"given":"Patrick","family":"Hwu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Melanoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0184-0717","authenticated-orcid":false,"given":"Khaled M.","family":"Elsayes","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 7 Department of Abdominal Imaging, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-851X","authenticated-orcid":false,"given":"Hussein A.","family":"Tawbi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Melanoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6173-9074","authenticated-orcid":false,"given":"Jared K.","family":"Burks","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 9 Department of Leukemia, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5926-3460","authenticated-orcid":false,"given":"Chantale","family":"Bernatchez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Melanoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0977-0912","authenticated-orcid":false,"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Melanoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2321-6894","authenticated-orcid":false,"given":"Kunal","family":"Rai","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 3 Department of Genomic Medicine, , Houston, Texas."},{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 4 MDACC Epigenomics Therapy Initiative (METI), , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4449-7461","authenticated-orcid":false,"given":"Gregory","family":"Liz\u00e9e","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Melanoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4079-6632","authenticated-orcid":false,"given":"Suhendan","family":"Ekmekcioglu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Melanoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8944-1547","authenticated-orcid":false,"given":"Adi","family":"Diab","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 1 Department of Melanoma Medical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"2026090103070838700_bib1","first-page":"641","article-title":"Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells","volume":"150","author":"Nestle","year":"1997","journal-title":"Am J Pathol"},{"key":"2026090103070838700_bib2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1097-0215(19960927)68:1&lt;1::AID-IJC1&gt;3.0.CO;2-V","article-title":"Human renal-cell carcinoma tissue contains dendritic cells","volume":"68","author":"Thurnher","year":"1996","journal-title":"Int J Cancer"},{"key":"2026090103070838700_bib3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1084\/jem.183.1.87","article-title":"Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines","volume":"183","author":"Zitvogel","year":"1996","journal-title":"J Exp Med"},{"key":"2026090103070838700_bib4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1084\/jem.183.1.283","article-title":"Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity","volume":"183","author":"Celluzzi","year":"1996","journal-title":"J Exp Med"},{"key":"2026090103070838700_bib5","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1182\/blood.v99.5.1676","article-title":"In vivo manipulation of dendritic cells to induce therapeutic immunity","volume":"99","author":"Merad","year":"2002","journal-title":"Blood"},{"key":"2026090103070838700_bib6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1146\/annurev.immunol.16.1.111","article-title":"CD40 and CD154 in cell-mediated immunity","volume":"16","author":"Grewal","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"2026090103070838700_bib7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jlb.67.1.2","article-title":"CD40-CD40 ligand","volume":"67","author":"van Kooten","year":"2000","journal-title":"J Leukoc Biol"},{"key":"2026090103070838700_bib8","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1158\/1078-0432.CCR-06-1893","article-title":"Prospect of targeting the CD40 pathway for cancer therapy","volume":"13","author":"Vonderheide","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2026090103070838700_bib9","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/10503","article-title":"Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40","volume":"5","author":"Sotomayor","year":"1999","journal-title":"Nat Med"},{"key":"2026090103070838700_bib10","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1038\/s41467-017-01572-7","article-title":"Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain","volume":"8","author":"Singh","year":"2017","journal-title":"Nat Commun"},{"key":"2026090103070838700_bib11","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1016\/j.celrep.2016.05.058","article-title":"CD40 stimulation obviates innate sensors and drives T cell immunity in cancer","volume":"15","author":"Byrne","year":"2016","journal-title":"Cell Rep"},{"key":"2026090103070838700_bib12","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"2026090103070838700_bib13","doi-asserted-by":"publisher","first-page":"e27615","DOI":"10.4161\/onci.27615","article-title":"Understanding the influence of the tumor microenvironment on macrophage responses to CD40 agonists","volume":"3","author":"Luheshi","year":"2014","journal-title":"Oncoimmunology"},{"key":"2026090103070838700_bib14","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/10495","article-title":"CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy","volume":"5","author":"Diehl","year":"1999","journal-title":"Nat Med"},{"key":"2026090103070838700_bib15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/8426","article-title":"CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help","volume":"5","author":"French","year":"1999","journal-title":"Nat Med"},{"key":"2026090103070838700_bib16","doi-asserted-by":"publisher","first-page":"8022","DOI":"10.1073\/pnas.1918971117","article-title":"Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity","volume":"117","author":"Morrison","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026090103070838700_bib17","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jhep.2020.11.037","article-title":"CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma","volume":"74","author":"Diggs","year":"2021","journal-title":"J Hepatol"},{"key":"2026090103070838700_bib18","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-17-3821","article-title":"Radiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer","volume":"78","author":"Rech","year":"2018","journal-title":"Cancer Res"},{"key":"2026090103070838700_bib19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 agonist antibodies in cancer immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu Rev Med"},{"key":"2026090103070838700_bib20","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1158\/1078-0432.CCR-12-2064","article-title":"Agonistic CD40 antibodies and cancer therapy","volume":"19","author":"Vonderheide","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026090103070838700_bib21","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00262-020-02814-2","article-title":"APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application","volume":"70","author":"Filbert","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2026090103070838700_bib22","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"2026090103070838700_bib23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"2026090103070838700_bib24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"2026090103070838700_bib25","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"2026090103070838700_bib26","doi-asserted-by":"publisher","first-page":"eaar3342","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci Transl Med"},{"key":"2026090103070838700_bib27","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"2026090103070838700_bib28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ccell.2020.11.015","article-title":"Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma","volume":"39","author":"Grasso","year":"2021","journal-title":"Cancer Cell"},{"key":"2026090103070838700_bib29","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1038\/s41467-021-24897-w","article-title":"Author Correction: the T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival","volume":"12","author":"Valpione","year":"2021","journal-title":"Nat Commun"},{"key":"2026090103070838700_bib30","doi-asserted-by":"publisher","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma","volume":"27","author":"Senzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026090103070838700_bib31","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026090103070838700_bib32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40425-016-0116-2","article-title":"Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study","volume":"4","author":"Kaufman","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2026090103070838700_bib33","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.annonc.2019.12.008","article-title":"Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients","volume":"31","author":"Algazi","year":"2020","journal-title":"Ann Oncol"},{"key":"2026090103070838700_bib34","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1158\/2159-8290.CD-20-1546","article-title":"Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma","volume":"11","author":"Haymaker","year":"2021","journal-title":"Cancer Discov"},{"key":"2026090103070838700_bib35","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","article-title":"SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase ib, multicenter study","volume":"8","author":"Ribas","year":"2018","journal-title":"Cancer Discov"},{"key":"2026090103070838700_bib36","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","article-title":"Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov"},{"key":"2026090103070838700_bib37","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1158\/1078-0432.CCR-18-0469","article-title":"Intratumoral G100, a TLR4 agonist, induces antitumor immune responses and tumor regression in patients with merkel cell carcinoma","volume":"25","author":"Bhatia","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026090103070838700_bib38","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/10428194.2021.2010057","article-title":"Phase \u00bd study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma","volume":"63","author":"Halwani","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"2026090103070838700_bib39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13045-022-01377-2","article-title":"Pembrolizumab combined with low-dose cyclophosphamide and intra-tumoral injection of the toll-like receptor 4 agonist G100 in patients with advanced pretreated soft tissue sarcoma: results from the PEMBROSARC basket study","volume":"15","author":"Spalato-Ceruso","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026090103070838700_bib40","doi-asserted-by":"publisher","first-page":"711673","DOI":"10.3389\/fonc.2021.711673","article-title":"Intra-Tumoral activation of endosomal TLR pathways reveals a distinct role for TLR3 agonist dependent type-1 interferons in shaping the tumor immune microenvironment","volume":"11","author":"Thomas","year":"2021","journal-title":"Front Oncol"},{"key":"2026090103070838700_bib41","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2026090103070838700_bib42","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026090103070838700_bib43","doi-asserted-by":"publisher","first-page":"6286","DOI":"10.1158\/1078-0432.CCR-13-1320","article-title":"A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma","volume":"19","author":"Beatty","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2026090103070838700_bib44","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study","volume":"22","author":"O\u2019Hara","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026090103070838700_bib45","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","article-title":"Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer","volume":"27","author":"Byrne","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026090103070838700_bib46","doi-asserted-by":"publisher","first-page":"101077","DOI":"10.1016\/j.iotech.2025.101077","article-title":"Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial)","volume":"29","author":"Alshatti","year":"2025","journal-title":"Immunooncol Technol"},{"key":"2026090103070838700_bib47","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.ccell.2025.07.013","article-title":"Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer","volume":"13","author":"Osorio","year":"2025","journal-title":"Cancer Cell"},{"key":"2026090103070838700_bib48","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026090103070838700_bib49","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","article-title":"Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma","volume":"34","author":"Daud","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026090103070838700_bib50","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","article-title":"Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab","volume":"22","author":"Weide","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026090103070838700_bib51","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1002\/cam4.5070","article-title":"Comparing the associations between host and tumor factors with survival outcomes with anti-PD-1 immunotherapy in metastatic melanoma","volume":"12","author":"Koczka","year":"2023","journal-title":"Cancer Med"},{"key":"2026090103070838700_bib52","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1038\/s41591-021-01544-x","article-title":"A phase \u00bd trial of an immune-modulatory vaccine against IDO\/PD-L1 in combination with nivolumab in metastatic melanoma","volume":"27","author":"Kjeldsen","year":"2021","journal-title":"Nat Med"},{"key":"2026090103070838700_bib53","doi-asserted-by":"publisher","first-page":"e006755","DOI":"10.1136\/jitc-2023-006755","article-title":"Long-term follow-up of anti-PD-1 na\u00efve patients with metastatic melanoma treated with IDO\/PD-L1 targeting peptide vaccine and nivolumab","volume":"11","author":"Lorentzen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026090103070838700_bib54","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat Med"},{"key":"2026090103070838700_bib55","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1158\/2767-9764.CRC-23-0550","article-title":"Neoadjuvant CD40 agonism remodels the tumor immune microenvironment in locally advanced esophageal\/gastroesophageal junction cancer","volume":"4","author":"Soto","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2026090103070838700_bib56","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/1078-0432.CCR-23-0475","article-title":"A phase II trial of the CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy","volume":"30","author":"Weiss","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026090103070838700_bib57","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","article-title":"DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors","volume":"8","author":"McGinnis","year":"2019","journal-title":"Cell Syst"},{"key":"2026090103070838700_bib58","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat Biotechnol"},{"key":"2026090103070838700_bib59","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41592-018-0033-z","article-title":"SAVER: gene expression recovery for single-cell RNA sequencing","volume":"15","author":"Huang","year":"2018","journal-title":"Nat Methods"},{"key":"2026090103070838700_bib60","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41588-021-00790-6","article-title":"ArchR is a scalable software package for integrative single-cell chromatin accessibility analysis","volume":"53","author":"Granja","year":"2021","journal-title":"Nat Genet"},{"key":"2026090103070838700_bib61","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1126\/science.aab1601","article-title":"Multiplex single cell profiling of chromatin accessibility by combinatorial cellular indexing","volume":"348","author":"Cusanovich","year":"2015","journal-title":"Science"},{"key":"2026090103070838700_bib62","doi-asserted-by":"publisher","first-page":"R137","DOI":"10.1186\/gb-2008-9-9-r137","article-title":"Model-based analysis of ChIP-seq (MACS)","volume":"9","author":"Zhang","year":"2008","journal-title":"Genome Biol"},{"key":"2026090103070838700_bib63","doi-asserted-by":"publisher","first-page":"e004371","DOI":"10.1136\/jitc-2021-004371","article-title":"Spontaneous tumor regression following COVID-19 vaccination","volume":"10","author":"de Sousa","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026090103070838700_bib64","doi-asserted-by":"publisher","first-page":"14049","DOI":"10.1038\/ncomms14049","article-title":"Massively parallel digital transcriptional profiling of single cells","volume":"8","author":"Zheng","year":"2017","journal-title":"Nat Commun"},{"key":"2026090103070838700_bib65","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"2026090103070838700_bib66","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13059-021-02584-9","article-title":"Comparison and evaluation of statistical error models for scRNA-seq","volume":"23","author":"Choudhary","year":"2022","journal-title":"Genome Biol"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-25-1551\/3772188\/cd-25-1551.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-25-1551\/3821408\/cd-25-1551.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/9\/1780\/3824546\/cd-25-1551.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/9\/1780\/3824546\/cd-25-1551.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:08:05Z","timestamp":1788246485000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/9\/1780\/787678\/Intratumoral-Sotigalimab-with-Pembrolizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":66,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,4,21]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-25-1551","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}